Braftovi Unión Europea - español - EMA (European Medicines Agency)

braftovi

pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - agentes antineoplásicos - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.

Mektovi Unión Europea - español - EMA (European Medicines Agency)

mektovi

pierre fabre medicament - binimetinib - melanoma - agentes antineoplásicos - binimetinib en combinación con encorafenib está indicado para el tratamiento de pacientes adultos con irresecables o melanoma metastásico con gen braf v600 mutation.

Paxlovid Unión Europea - español - EMA (European Medicines Agency)

paxlovid

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Braftovi 50 mg Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

braftovi 50 mg

pfizer inc estados unidos - cada cápsula contiene: encorafenib (a)? 50.000mg - capsulas - cada cápsula contiene: encorafenib (a)? 50.000mg

Braftovi 75 mg Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

braftovi 75 mg

pfizer inc estados unidos - cada cápsula dura contiene: encorafenib (a)? 75.000mg - capsula dura - cada cápsula dura contiene: encorafenib (a)? 75.000mg